Proxygen Names Chiara Conti as Chief Scientific Officer

Proxygen GmbH, a Vienna-based biotechnology company, has appointed Chiara Conti, Ph.D., as its new Chief Scientific Officer. Dr. Conti, formerly of Blueprint Medicines, is known for her expertise in targeted protein degradation and her success in advancing drug candidates to the clinical stage. At Proxygen, she will focus on moving the company's molecular glue degraders from discovery to clinical development.

Dr. Conti's arrival comes as Proxygen plans to expand its platform beyond degradation to a broader range of proximity-based therapeutics. The company aims to systematically exploit its scientific foundation to create novel therapies, increasing its therapeutic reach and addressing high-value targets.

Proxygen has established multiple pharmaceutical partnerships, including with Merck & Co., highlighting industry interest in their proximity-inducing drug approach.